同方康泰(01312.HK)中期淨虧3117.8萬港元 同比收窄58.71%
格隆匯8月29日丨 同方康泰(01312.HK)公吿,截至2022年6月30日止6個月未經審核中期,公司實現持續經營業務收入4.51億港元,同比增加17.15%;股東應占虧損3117.8萬港元,同比收窄58.71%;基本每股虧損0.56港仙。
2022年上半年,COVID-19病例在中國內地偶有反彈,以及部分原材料成本攀升。集團醫藥業務面對挑戰,迎難而上,迅速採取應對措施,儘量減少不利因素的影響,並實現了業績的提升。
截至2022年6月30日止6個月,集團醫藥業務收入較2021年同期增長20.8%。截至2022年6月30日止6個月的純利為670萬港元,較2021年同期增加1575%。純利大幅增加,主要是由於同方藥業於2022年上半年並無經歷一名主要產品供應商無法按時交付生產材料的情況,而同方藥業於2021年上半年經歷有關無法按時交付而導致對其於該期間的業績構成負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.